At a glance
- Originator Sanwa Kagaku Kenkyusho
- Class Anti-ischaemics
- Mechanism of Action L-selectin inhibitors; P selectin inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Retinal disorders
Most Recent Events
- 23 Apr 2001 Preclinical development for Retinal disorders in Japan (Unknown route)